Hypertension is one of the main causes of premature death in the world; also, it is associated with several bone alterations. Preclinical studies have demonstrated delayed alveolar bone healing in hypertensive rats. However, losartan has been favorable for consolidation of bone grafts and reduction in active periodontitis. Therefore, losartan is suggested to be effective in bone formation stages, as well as in the synthesis of matrix proteins and mineralization. Objectives: To evaluate the alveolar bone dynamics in hypertensive rats treated with losartan by laser confocal microscopy and histological analysis. Methodology: Thirty-two rats, 16 spontaneously hypertensive rats (SHR) and 16 Wistar albinus rats, treated or not with losartan (30 mg/kg/day) were used. Calcein fluorochrome at 21 days and alizarin red fluorochrome at 49 days were injected in rats (both 20 mg/kg).
Introduction
Hypertension is a chronic disease with the highest number of premature deaths and care assistance in the world. 1, 2 Its high prevalence reaches about one in three young adults in the world, and this number is estimated to increase. 3 In addition to cardiovascular diseases, hypertension is associated with chronic renal failure, stroke, and bone abnormalities, such as: abnormal calcium metabolism, 4 Renin-angiotensin system inhibition is a target for hypertension control. 11 Then, angiotensin II receptor blockers can prevent vasoconstriction and high blood pressure. 12 In addition, angiotensin II enhances bone resorption by increasing RANKL and osteoclastic activation. 6, 13, 14 Also, it has effects of osteoblastic lineage changing, 15, 16 by decreasing the expression of osteogenesis-related transcription factors via the AT1 receptor, such as Runx2, Msx2, and osteocalcin. 15 Losartan, as an angiotensin II receptor blocker, 17 has attracted interest not only for being a vasodilator, but also for its positive effects in bone metabolism. 18, 19 Preclinical studies have reported benefits of losartan on bone fracture healing and reduction in bone fracture risk. 20 They also reported improved bone graft healing. 10 In in vitro 18 and in vivo studies, 21 losartan significantly enhanced bone density by decreasing osteoclastogenesis and increasing osteoblastic activity.
Therefore, a topic to be evaluated referred to how antihypertensive drugs interfere in alveolar bone dynamics.
The action of losartan in the renin-angiotensin system, and its consequent influence on bone metabolism, is widely studied. 19, 22, 23 Fluorochrome application 21 days after beginning drug treatment, the fluorochrome calcein was administered intramuscularly (20 mg/kg). Alizarin red fluorochrome was also used intramuscularly at a dose of 20 mg/kg for each animal after more 28 days, according to previous studies. [25] [26] [27] The first injected calcein fluorochrome indicates calcium deposition in old bone and the subsequent alizarin fluorochrome in the newly-formed bone.
Euthanasia
All animals were submitted to euthanasia 67 days after drug treatment with a intravenously lethal excessive anesthetic dose (60 mg/kg, Tiopental Cristália Ltda; Itapira, SP, Brazil). Therefore, this experimental period is adequate to characterize the modeling or remodeling process of old bone into new bone indicated by fluorochormes and histology.
Laboratory processing
The right side of the maxilla was removed and fixed in 10% formaldehyde. After 48 hours, they were washed 24 hours in running water and dehydrated in an increasing alcohol sequence. The samples were 
Histological analysis
Later, the left hemi-maxilla was washed 24 hours in running water and decalcified in 10% EDTA for 6 weeks. They were washed for 24 h, dehydrated through an alcohol sequence, cleared in xylene and embedded in paraffin (Merck, Kenilworth, NJ, USA).
5-µm thick sections were cut with a microtome and mounted on glass slides. Alizarin red and Stevenel's blue-stained slides were captured using a Nikon microscope (Eclipse 80i, Shinagawa, Tokyo, Japan).
Bone tissue morphology was qualitatively evaluated, establishing comparison between the groups. The slides were photomicrographs magnified from the originals by 10x.
Statistical analysis
The GraphPad Prism 7.0 profiler (GraphPad Software, La Jolla, USA) was used for statistical test.
Shapiro-Wilk test (p<0.05) was performed to verify homoscedasticity and whether the results were parametric. After confirming the normal distribution, Anova test was performed followed by Tukey post-test for multiple comparisons when necessary. For all tests, the p-value considered as significant was p<0.05.
Results
Systolic blood pressure and body weight 
Qualitative analysis

Quantitative analysis
Bone volume formed
The highest bone volume formed occurred in Wistar Losartan with 65650572 μm 3 , showing statistical difference compared with all other groups (p<0.05; Figure 4A ).
Mineralized surface
Wistar Losartan showed the highest percentage, and no difference with the SHR group losartan (118235 versus 71638 μm 2 ; p=0.1642) ( Figure 4C ).
Bone formation rate
The Wistar Losartan also revealed the highest Losartan improves alveolar bone dynamics in normotensive rats but not in hypertensive rats J Appl Oral Sci. 2019;27:e20180574 5/9 bone formation rate with 53.9 μm 3 / μm 2 /day, showing statistical difference compared with both hypertensive animal groups (p<0.05; Figure 4D ).
Mineral apposition rate
SHR losartan showed higher daily mineral apposition rate compared with Wistar (16.01 versus 10.58 μm, p=0.0141) and SHR (16.01 versus 10.91 μm, p=0.014) and no difference with Wistar Losartan (16.01 versus 13.7 μm, p=0.361) ( Figure 4E ).
Calcein
The highest Calcein fluorochrome biomarker values were in Wistar, with statistical difference when compared with SHR (108578 versus 33052 μm 2 ; p=0.0002) and SHR Losartan (108578 versus 50799 μm 2 ; p<0.0001) ( Figure 4F ). Figure 5 provides an overview of the bone dynamics MULINARI-SANTOS G, SANTOS JS, PALIN LP, SILVA AC, ANTONIALI C, FAVERANI LP, OKAMOTO R Figure 2 -Systolic blood pressure and body weight. Graph with the systolic blood pressure measured by tail-cuff indirect plethysmography using the Physiograph®, MK-III-S plethysmograph (Narco Bio-systems, Houston, Texas). The * indicates statistical difference of the SHR blood pressure group compared with the others (p<0.05). Additionally, the body weights were checked during the experiment and were similar between the groups treated with balanced diet (Ração Mogiana Alimentos SA, Campinas, Brazil) Losartan improves alveolar bone dynamics in normotensive rats but not in hypertensive rats Erythrocytes indicate the presence of the blood vessels. No inflammations signs were observed. Again, these histological findings applied to all groups.
Histological analysis
Discussion
In addition to cardiovascular diseases, 3 Results also showed lower mineralized surface in hypertensive animals.
Previous studies corroborate the favorable losartan effect in normotensive animals' alveolar bone dynamics. 10, 19, 22, 23 One example is the improvement in bone graft consolidation in wistar rats treated with losartan. 10 Other preclinical studies have shown decreased osteoclastogenesis by losartan, reducing the orthodontic movement 19 and periodontal bone loss. 22, 23 Interestingly, in situations not related to hypertension, such as osteoporosis, this drug could increase bone mineral density in ovarectomized rats' femurs. 21 Also, other previous findings reveal an angiotensin II increase in hypertension, and its catabolic action on bone metabolism. 8, 12 Diversely, estrogen decreased angiotensin II levels. 33 Thus, osteoprotective effect of losartan was confirmed in fractures of osteoporotic animals, in which losartan increased microcirculation and consolidation of bone fractures. 21 Additional study reported the ability of losartan to enhance endothelial cell proliferation 34 and to correct hypertensive patients' arterial structure. 35 Thus, angiotensin II blocking through losartan has implications beyond simply controlling blood pressure. Regarding vascular activity, its increase in microcirculation and angiogenesis can accentuate cellular activity and subsequent mineral apposition, as in normotensive animals. However, the same effect was not observed in hypertensive animals, which can be explained by a possible exacerbated osteoclastogenic activity in this model as demonstrated in previous studies. 5, 6 Regarding the clinical relevance of this study, we highlight the anabolic effect of losartan on bone metabolism in the homeostasis physiological condition. Our findings corroborate a greater mineral deposition in normotensive animals treated with losartan. Although bone dynamics involves a complex mechanism, 26 we observed two crucial effects of losartan. First, its vasodilatory action possibly increased the plasma calcium supply, and, consequently, bone mineral deposition. Second, its performance on RANKL/OPG system can increase osteoblastic activity and reduce osteoclastogenesis, as validated in previous studies. 6, 15, 18, 22 For the clinical relevance, studies on the use of losartan to improve osseointegration in normotensive individuals or low bone density condition might be suggested. Also, regarding Implantology, the action of losartan on bone reconstruction with biomaterials can be analyzed to evaluate the occurrence of these benefits. In addition, in Periodontology, it must be investigated whether losartan can prevent or diminish periodontal bone loss. Corroborating our considerations, recent clinical studies showed antihypertensives as responsible for the increased success rate of osseointegrated dental implants. 36, 37 Another clinical study shows the reduction in fracture risk in hemodialysis patients treated with antihypertensive drugs. 31 
